Abera Bioscience AB (FRA:8WK)

Market Cap	12.29M +137.9%
Revenue (ttm)	1.10M -18.7%
Net Income	-965.89K
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40
Average Volume	2
Open	0.5300
Previous Close	0.5450
Day's Range	0.5300 - 0.5500
52-Week Range	0.3420 - 0.8350
Beta	n/a
RSI	50.30
Earnings Date	Feb 12, 2026

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8WK

Financial Performance

In 2025, Abera Bioscience AB's revenue was 11.89 million, a decrease of -18.74% compared to the previous year's 14.63 million. Losses were -10.45 million, 850.3% more than in 2024.

Financial numbers in SEK